Misoprostol + Mifepristone Vs. Misoprostol Alone in Second Trimester Termination of Pregnancy

Published On: 21 Aug, 2023 12:47 PM | Updated On: 21 Aug, 2023 12:54 PM

Misoprostol + Mifepristone Vs. Misoprostol Alone in Second Trimester Termination of Pregnancy

The present study assessed and compared the efficacy and safety of mifepristone and misoprostol combination versus misoprostol alone for second-trimester termination of pregnancy.

The study included 100 women for second-trimester termination of pregnancy, divided into two equal groups, where Group A patients received 200 mg of oral mifepristone followed by 400 mcg of vaginal misoprostol after 48 h, and then 400 mcg of vaginal misoprostol every three hourly until complete expulsion or a maximum of 6 doses. Group B patients received 400 mcg of vaginal misoprostol every three hours until complete expulsion or a maximum of 6 doses.

The study observed-

  • Complete abortion in 92% and 72% of cases in Group A and Group B, respectively. 
  • The mean induction abortion interval was 11.59 ± 2.71 h in Group A and 15.57 ± 2.27 h in Group B.
  • The combination regimen required less average dose of misoprostol than the misoprostol alone group. 
  • The combination regimen had lesser side effects than the misoprostol alone group.

The combination of mifepristone and misoprostol is a safer and more effective alternative than using misoprostol alone for terminating a pregnancy in the second trimester.

Nayak AK, Mishra S, Mishra S., et al. Randomised Control Study of Misoprostol and Mifepristone versus Misoprostol Alone in Second Trimester Termination of Pregnancy. J Obstet Gynecol India. 2023. https://doi.org/10.1007/s13224-023-01800-9

user
IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team
Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks